For the first time, patients whose prostate cancer has not spread will be eligible for the drug abiraterone in England, after ...

Thousands of men battling prostate cancer are set to gain access to a life-extending drug on the NHS following a significant ...

Investigators at the UCLA Health Jonsson Comprehensive Cancer Center have opened a clinical trial that will look at whether ...

NHS England has announced that men whose high-risk prostate cancer has not yet spread will be able to receive the drug, ...

Ernie Strauss and Ronald Wakefield, who met through the patient navigation program of Northside Hospital, have built a ...

Study results are based on Surveillance, Epidemiology, and End Results-Medicare data for 166,581 patients receiving surgery or radiation for localized prostate cancer.

Thousands more men with prostate cancer will be eligible for a life-extending drug on the NHS. The move means the drug, known ...

In a previous study, the researchers showed that PSA scores can impact both doctor and patient behavior, leading to biopsy ...

The latest edition of an annual report finds new cases continue to rise and outcomes have worsened for some cancers.

Blue Earth Therapeutics today announced that the first patients in the UK have been administered with the investigational ...

Researchers at the UCLA Health Jonsson Comprehensive Cancer Center have launched a clinical trial, called ANDROMEDA, to ...